SEC Form 4 · accession 0001203311-19-000004
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David W Gryska
Director
Period of report
Jan 8, 2019
Accepted (ET)
Jan 10, 2019 · 9:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 8, 2019 | M | 5,000 | $12.76 | A | 50,050 | D | |
| Common StockF2,F3 | Jan 8, 2019 | S | 5,000 | $65.04 | D | 45,050 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F4 | $12.76 | Jan 8, 2019 | M | 5,000 | D | Jan 8, 2019 | May 21, 2020 | Common Stock | 5,000 | 12,500 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2Reflects sales of common stock executed in multiple transactions at prices ranging from $65.00 to $65.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F4The option vested in full on May 20, 2011.